Loading clinical trials...

Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fasted Conditions | Clinical Trials | Clareo Health

COMPLETEDNANCT00893542

Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fasted Conditions

The objective of this study was to prove the bioequivalence of Mycophenolate Mofetil 250 mg Capsules under fasted conditions.

Lead sponsor: Roxane Laboratories•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

COMPLETEDNA

Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fed Conditions

NCT00893958 · Prophylaxis of Organ Rejection

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 23, 2018Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment37

Start dateNov 2005

Last updatedJan 23, 2018

Condition

Prophylaxis of Organ Rejection

Locations shown

CEDRA Clinical Research, LLC

Austin, Texas

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 23, 2018Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions